Telix Pharmaceuticals (ASX:TLX) is an Australian-founded global radiopharmaceutical company developing diagnostic and therapeutic products that combine targeted biological molecules with radioactive isotopes. The company's commercial backbone is Illuccix, a kit for the preparation of gallium-68 PSMA-PET imaging in prostate cancer, which is now approved across multiple major markets including Australia, the United States, the United Kingdom, Canada, Brazil and Europe, with regulatory submissions progressing in markets such as China.

Beyond Illuccix, Telix has built a portfolio that includes Gozellix, a follow-on PSMA-PET product approved by the US FDA, and a deepening pipeline of clinical-stage candidates covering brain cancer imaging (TLX101-Px, recently the subject of FDA acceptance for a new drug application for Pixclara), kidney cancer imaging, prostate cancer therapy (the Phase 3 ProstACT Global study of TLX591-Tx), and adjacent oncology indications. The strategy is to build an integrated radiopharma platform that pairs diagnostics with therapeutics, sometimes called a theranostic model.

Sector and industry analysis: radiopharmaceuticals are coming of age

Radiopharmaceuticals have moved from a niche corner of nuclear medicine to one of the most exciting subsectors of oncology Drug Development. The catalyst was the validation of Lutetium-177-based therapies in prostate cancer and neuroendocrine tumours, which delivered meaningful overall-survival benefits in pivotal trials. That has triggered a wave of pharma deal-making and accelerated Investment in isotope Supply, Manufacturing infrastructure and targeted ligands.

Diagnostic radiopharmaceuticals such as Illuccix occupy a complementary role. PSMA-PET imaging is increasingly recognised as the standard of care for staging and restaging prostate cancer, with clinical guidelines progressively embedding the technology into treatment pathways. As more patients are imaged at earlier disease stages, the addressable market expands.

Telix sits at the intersection of these two Demand curves. Diagnostic Revenue funds the broader platform, while therapeutic candidates offer the optionality of step-change Earnings if pivotal trials read out positively. Few ASX-listed biotechs have this dual engine.

Why the stock deserves a Buy rating

Revenue growth in 2025 was significant, with full-year sales up materially year on year, and the company has issued 2026 revenue guidance that points to continued double-digit growth even before any pipeline approvals contribute.

Importantly, the Buy thesis here is fundamental and long-dated rather than a pure trial-readout bet. It rests on the durability of Illuccix demand, the gradual broadening of the global PSMA-PET market, and the optionality embedded in pipeline candidates including the brain-cancer imaging agent Pixclara, kidney-cancer imaging programs and the ProstACT Global therapeutic study. Investors must accept biotech-typical Volatility, but the underlying Business case is more grounded than the share price action suggests.

There is also a broader strategic argument. Telix has built and continues to build manufacturing capacity, distribution agreements and clinical trial relationships that are extremely difficult for a new entrant to replicate. Radiopharmaceutical supply chains depend on time-critical handling, regulated isotope production and tight clinical workflows, all of which Telix has invested in for years. That infrastructure becomes a moat in its own right and is one of the reasons global pharma majors continue to look at the company as both a partner and a potential consolidation candidate.

Key growth drivers through 2026 and beyond

The first driver is geographic expansion of Illuccix, including any contribution from new markets and continued penetration in established markets as PSMA-PET becomes standard of care. The second is the launch ramp of Gozellix in the United States as a second-generation PSMA-PET option that broadens Telix's commercial footprint in its largest market.

The third driver is the pipeline. Pixclara, the brain-cancer imaging candidate, has been resubmitted to the US FDA following earlier issues, with corresponding Marketing authorisation applications progressing in Europe. Pixlumi is the European Brand for the same program. Kidney-cancer imaging programs have also progressed through pivotal phases, and the therapeutic pillar is being built around the ongoing Phase 3 ProstACT Global study of TLX591-Tx in prostate cancer, where the lead-in phase reported encouraging safety and dosimetry signals.

The fourth driver is manufacturing and isotope supply, with continued investment in production capacity across multiple jurisdictions. That infrastructure is itself a strategic asset given supply constraints in the broader radiopharmaceutical industry.

Capital allocation and reinvestment discussion

Telix does not pay a Dividend, which is appropriate for a growth-stage company with a deep pipeline and an active investment in manufacturing infrastructure. Cash generated by Illuccix and Gozellix is being directed into clinical development, regulatory submissions, geographic expansion, manufacturing capacity, and selected acquisitions and partnerships.

For investors used to ASX dividend payers, this is a different proposition. The return is expected to come through capital growth, not income, with the implicit promise that reinvested cash will compound at higher returns than a near-term payout would deliver. The track record so far has been mixed, with commercial execution strong but regulatory setbacks on individual pipeline Assets denting confidence in the past twelve months. The pipeline's depth, however, means a single regulatory event does not break the broader story.

Capital allocation discipline becomes especially important when growth Equity narratives are challenged. Investors should watch for evidence that cash burn on lower-priority programs is being managed, and that capacity investment is being timed to demand rather than aspiration.

Risks investors should watch

Clinical and Regulatory Risk is the most obvious. Pipeline programs face genuine probability of further trial failures, manufacturing-comparability issues or extended FDA review timelines. The recent path of certain candidates makes clear that approvals in radiopharmaceuticals are not guaranteed even after strong clinical signals.

Disclosure and governance risk is a second category. Telix has been the subject of regulator and investor focus over its disclosures in earlier periods, including reported SEC interest. While this does not by itself impair the commercial business, it can weigh on multiples and constrain institutional ownership.

Competitive risk is the third category. Several global pharma majors and emerging biotech competitors are investing aggressively in PSMA-PET imaging and Lutetium-177 therapy, both adjacent to Telix's core platform. Competition can compress pricing and slow share gains. Fourth, commercial execution risk on the launch of new diagnostic products, particularly outside the United States, can affect the pace of revenue growth even where the underlying market backdrop is strong.

What could move the share price next

Near-term, the next catalysts include the FDA review timeline for Pixclara and parallel European decisions for Pixlumi, ongoing updates on the Phase 3 ProstACT Global study, and quarterly trading updates that continue to demonstrate Illuccix and Gozellix growth.

A clean resolution of any outstanding manufacturing-comparability questions on key programs would also support sentiment, as would clarity around any remaining regulatory or governance enquiries. On the negative side, a delay or rejection of a major pipeline submission, or a meaningful clinical setback in ProstACT Global, would weigh on the stock.

Longer term, the strongest single share-price driver would be a positive readout from a pivotal therapeutic program, which would re-rate Telix from a diagnostics-led story into a fully integrated theranostic platform. That is the asymmetric upside the Buy rating ultimately points toward.

Conclusion

Telix Pharmaceuticals is a more grounded biotech story than the share-price action of the past year suggests. The commercial base is real and growing strongly, the pipeline offers genuine asymmetric upside if pivotal programs continue to advance, and the market opportunity in radiopharmaceuticals is structurally supported by clinical guideline shifts and continued pharma sector investment.

The Buy rating comes with explicit acknowledgement of clinical, regulatory and governance risks, which require investors to size positions modestly and to be patient with timelines that can extend beyond original guidance. For investors with the appropriate risk appetite and time horizon, however, Telix arguably offers one of the more interesting growth profiles in ASX healthcare, with both an established revenue engine and a deep pipeline of catalysts that can drive a multi-year re-rating.